FLAGGING OF PURCHASE OF SHARES AND MAJOR CHANGE OF HOLDINGS BY PMDR IN EEVIA HEALTH PLC
Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc (”Eevia” or ”The Company”), has purchased 525 800 shares in Eevia Health Plc.
Stein Ulve, CEO of Eevia, has purchased 525,700 shares in Eevia Health Plc through the subscription of new shares in the recent Rights issue in the Company, which was completed in July and shares delivered in mid-August. The price for the shares Ulve subscribed for was EUR 0,05 per share according to the terms of the Rights issue for subscriptions in Finland. Hence, Stein Ulve purchased the 525,700 shares for EUR 26,285.
Stein Ulve had 2,284,714 shares before the purchase, which represented 6.40% of the outstanding shares before the Rights issue (35,713,884 shares).
Stein Ulve now has 2,810,414 shares. The Rights issue was for 28,641,604 shares, and the total outstanding shares increased to 64,355,488. Hence, Stein Ulve’s new holding now equals 3,55% of the Company’s current outstanding shares. Due to the dilution from the Rights issue, his shareholding fell below the 5% level of the new outstanding total shares despite the purchase of shares.
Stein Ulve was also awarded 131,425 Warrants TO1 as part of the rights issue subscription. The subscription period is 18 August 2025 – 29 August 2025, and the share subscription price is determined by the volume-weighted average price of the Company's share on Spotlight between 31 July 2025 and 13 August 2025, with an applied discount of 25 percent. Stein Ulve has no other options or equity instruments in the Company, but the Board has indicated plans for implementing an option incentive program during 2024.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.